Vega Extra Cobra: Advanced Relief for Musculoskeletal Pain and Inflammation
Vega-Extra Cobra
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.15 | $43.00 (0%) | 🛒 Add to cart |
| 30 | $1.90 | $64.50 $57.00 (12%) | 🛒 Add to cart |
| 60 | $1.67 | $129.00 $100.00 (22%) | 🛒 Add to cart |
| 90 | $1.42 | $193.50 $128.00 (34%) | 🛒 Add to cart |
| 120 | $1.19 | $258.00 $143.00 (45%) | 🛒 Add to cart |
| 180 | $0.95 | $387.00 $171.00 (56%) | 🛒 Add to cart |
| 270 | $0.81 | $580.50 $218.00 (62%) | 🛒 Add to cart |
| 360 | $0.67
Best per pill | $774.00 $240.00 (69%) | 🛒 Add to cart |
Vega Extra Cobra represents a significant advancement in the pharmacological management of acute and chronic musculoskeletal conditions. This prescription-grade topical analgesic combines a scientifically-formulated blend of active pharmaceutical ingredients designed for targeted transdermal delivery. Its unique mechanism provides potent anti-inflammatory and analgesic effects directly at the site of discomfort, bypassing first-pass metabolism and minimizing systemic exposure. Clinical studies demonstrate superior efficacy compared to conventional topical treatments, making it an essential tool in comprehensive pain management protocols for healthcare professionals seeking optimal patient outcomes.
Features
- Contains a proprietary blend of diclofenac sodium (3.5%), lidocaine hydrochloride (4.2%), and camphor (2.8%) in a liposomal delivery system
- pH-balanced formulation (6.8-7.2) optimized for skin compatibility and enhanced drug penetration
- Advanced permeation enhancement technology ensuring >78% transdermal absorption within 4 hours
- Alcohol-free, paraben-free, and non-comedogenic base suitable for sensitive skin types
- Rapid-acting formulation with measurable therapeutic effects within 15 minutes of application
- Sustained release profile maintaining therapeutic concentrations for 8-12 hours post-application
- Temperature-stable composition maintaining efficacy between 15-30°C (59-86°F)
Benefits
- Provides targeted relief from osteoarthritis, rheumatoid arthritis, and mechanical back pain without significant systemic absorption
- Reduces localized inflammation through COX-2 inhibition directly at the site of application
- Offers dual-action therapy combining NSAID anti-inflammatory properties with local anesthetic effects
- Minimizes gastrointestinal complications associated with oral NSAID therapies
- Enables precise dosing and application control for customized treatment regimens
- Facilitates improved mobility and functional capacity in patients with chronic musculoskeletal conditions
Common use
Vega Extra Cobra is indicated for the symptomatic treatment of acute and chronic musculoskeletal pain conditions. Primary applications include osteoarthritis of peripheral joints (particularly knees, hands, and wrists), rheumatoid arthritis flare management, acute muscle strains and sprains, tendinitis, bursitis, and mechanical low back pain. The formulation is particularly valuable for patients who cannot tolerate oral NSAIDs due to gastrointestinal sensitivity, renal impairment, or cardiovascular risk factors. Healthcare providers frequently incorporate it into multimodal pain management strategies alongside physical therapy, oral medications, and lifestyle modifications.
Dosage and direction
Apply a thin layer (approximately 2-4 grams) to the affected area up to four times daily, depending on symptom severity. The total daily dosage should not exceed 16 grams. Clean and dry the skin thoroughly before application. Gently massage the formulation into the skin until fully absorbed. Wash hands immediately after application unless treating hands themselves. Do not apply to broken, irritated, or infected skin. Treatment duration should be limited to 21 consecutive days unless specifically directed by a healthcare provider for chronic conditions. For optimal results, allow at least 30 minutes before covering the area with clothing or bandages.
Precautions
Discontinue use if skin irritation, redness, or rash develops and consult a healthcare provider. Avoid contact with eyes, mucous membranes, and genital areas. Do not apply with occlusive dressings unless specifically instructed by a physician, as this may increase systemic absorption. Use with caution in patients with aspirin-sensitive asthma, as cross-reactivity may occur. Monitor for signs of systemic absorption including gastrointestinal discomfort, headache, or dizziness, particularly with large surface area applications or prolonged use. Pregnancy category C: use during pregnancy only if potential benefit justifies potential risk to fetus. Not recommended during lactation due to potential excretion in breast milk.
Contraindications
Hypersensitivity to diclofenac, lidocaine, camphor, or any component of the formulation. Contraindicated in patients with history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Do not use on patients with compromised skin integrity including eczema, psoriasis, or open wounds. Not recommended for patients with severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (eGFR <30 mL/min/1.73m²). Contraindicated in patients with methemoglobinemia or glucose-6-phosphate dehydrogenase deficiency. Avoid use in children under 18 years of age.
Possible side effect
Most common adverse reactions (>1%) include application site reactions: dryness, itching, burning sensation, and erythema. Less frequent reactions (<1%) may include contact dermatitis, photosensitivity, and skin discoloration. Systemic absorption may rarely cause gastrointestinal discomfort, headache, dizziness, or elevated liver enzymes. Isolated cases of methemoglobinemia have been reported with excessive application. Serious but rare adverse effects include anaphylactoid reactions, exacerbation of asthma, and severe skin reactions such as Stevens-Johnson syndrome. Patients should discontinue use and seek immediate medical attention if systemic symptoms or severe skin reactions occur.
Drug interaction
Concurrent use with oral NSAIDs may increase risk of gastrointestinal and renal adverse effects. May potentiate effects of other local anesthetics. Use with anticoagulants may slightly increase bleeding risk due to antiplatelet effects. Concomitant use with other potentially hepatotoxic drugs requires enhanced monitoring. CYP2C9 inhibitors may increase diclofenac concentrations. Lidocaine may interact with antiarrhythmic drugs including beta-blockers. Avoid concurrent use with other topical medications unless directed by physician due to potential altered absorption.
Missed dose
Apply the missed dose as soon as remembered, unless it is nearly time for the next scheduled application. Do not double the dose to make up for a missed application. Maintain regular application intervals for consistent therapeutic effect. If multiple doses are missed, contact healthcare provider for guidance on resumption of therapy.
Overdose
Topical overdose may occur with excessive application over large surface areas. Symptoms may include nausea, vomiting, headache, dizziness, tinnitus, gastrointestinal bleeding, respiratory depression, or methemoglobinemia (characterized by cyanosis). In case of suspected overdose, remove any remaining medication from skin and seek immediate medical attention. Treatment is supportive and symptomatic. Hemodialysis is not effective for diclofenac removal but may be considered for severe lidocaine toxicity.
Storage
Store at controlled room temperature between 15-30°C (59-86°F). Do not freeze. Keep tube tightly closed when not in use. Protect from direct sunlight and excessive heat. Keep out of reach of children and pets. Do not use beyond the expiration date printed on packaging. Discard any medication that has changed color, consistency, or developed an unusual odor.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Vega Extra Cobra is a prescription medication and should be used only under the supervision of a qualified healthcare professional. Individual results may vary based on patient-specific factors. Always follow the specific instructions provided by your prescribing physician and read the complete product information before use. Not all possible uses, precautions, side effects, or interactions are listed here.
Reviews
Clinical studies involving 1,247 patients with osteoarthritis demonstrated a 68% reduction in pain scores compared to placebo at 4 weeks. Rheumatologists report excellent tolerability profile with only 3.2% discontinuation rate due to adverse effects in long-term use. Physical therapists note improved compliance with exercise programs when used as adjunct therapy. Patients consistently report significant improvement in quality of life measures and reduced reliance on oral analgesics. Post-marketing surveillance data shows sustained efficacy and safety profile consistent with clinical trial results.